Where is CAMP4 located?

CAMP4 is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

Who is the current CEO of CAMP4?

Josh Mandel-Brehm of CAMP4. They have also founded 1 company.

How many employees does CAMP4 have?

As of May 31, 2026, the latest employee count at CAMP4 is 61.

Is CAMP4 a funded company?

CAMP4 is a funded company, having raised a total of $180M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round.

When was the latest funding round of CAMP4?

CAMP4's latest funding was a $***** Post IPO round on Sep 10, 2025, with participation from 7 investors.

Where does CAMP4 rank among its competitors?

CAMP4 ranks 44th amongst 527 active competitors, of which 193 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was CAMP4, which secured $100M in Sep, 2025.

Who are the top competitors of CAMP4?

CAMP4's top competitors include Alnylam, Spark Therapeutics and Strand Therapeutics. Among them, CAMP4 secured the most recent funding round in September, 2025.

CAMP4 - 2026 Company Profile, Team, Funding & Competitors

CAMP4 is a public company based in Cambridge (United States), founded in 2018. It operates as a Provider of a drug prediction and development tool for researchers. CAMP4 has raised $180M in funding from investors like Andreessen Horowitz, 5AM Ventures and Northpond Ventures. The company has 527 active competitors, including 193 funded and 127 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Strand Therapeutics.

Company Details

Provider of a drug prediction and development tool for researchers. The platform helps to code the discrete set of combinatorial rules used by any human cell type central to disease pathology. It uses machine learning algorithms to solve for druggable targets to control the output of any disease gene of interest.

Website: camp4tx.com
Social
Email ID: *****@camp4tx.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2018

Location

Cambridge, United States

Stage

Public

Total Funding

$180M in 5 rounds

Latest Funding Round

Post IPO, Sep 10, 2025, $*****

Investors

Andreessen Horowitz & 15 more

Ranked

44^th among 527 active competitors

Employee Count

61 as on May 31, 2026

Similar Companies

Alnylam & 664 more

Exit Details

Public

View CAMP4's full profile

CAMP4 is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MARAUDER THERAPEUTIS, INC. CIN: 811152476 , United States, Active	Dec 31, 1999	-	55 (As on Dec 31, 2024)	-

CAMP4 got listed on Oct 11, 2024.

Click here to take a look at CAMP4's IPO in detail

CAMP4 has raised a total funding of $180M over 5 rounds. Its latest funding round was a Post IPO round on Sep 10, 2025 for $*****. 7 investors participated in its latest round. CAMP4 has 16 institutional investors.

Here is the list of recent funding rounds of CAMP4:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 10, 2025	6805334	Post IPO	7079670	1982110	8752490	8411508
Jun 03, 2022	5561370	Series B	6441226	4200363	5297617	5AM Ventures & 5 more
Mar 05, 2021	6621959	Series B	8556606	1252078	Northpond Ventures & 1 more	Polaris Partners & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of CAMP4's funding rounds and investors

CAMP4's employee count trend

CAMP4 has 61 employees as of May 26. Here is CAMP4's employee count trend over the years:

Uncover CAMP4's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CAMP4 include Alnylam, Spark Therapeutics and Strand Therapeutics. Here is the list of Top 10 competitors of CAMP4, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	70/100
4th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
5th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
6th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
7th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Healthcap, F-Prime Capital & 10 others	69/100
8th	Generation Bio 2016, Cambridge (United States), Acquired	Developer of gene therapies for rare liver and eye diseases	$236M	Fidelity Investments, T. Rowe Price & 9 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, EDBI & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Danforth Advisors, Frazier Life Sciences & 2 others	67/100
44th	CAMP4 2018, Cambridge (United States), Public	Provider of a drug prediction and development tool for researchers	$180M	Flucas Ventures, The Kraft Group & 14 others	61/100